President Donald Trump made a historic move by signing an executive order in the Oval Office to expand access to cannabis, marking a significant shift in U.S. drug policy. The order reschedules marijuana from a Schedule 1 to a Schedule 3 controlled substance with legitimate medical uses. This decision comes after American patients suffering from various conditions, including extreme pain, incurable diseases, aggressive cancers, seizure disorders, and neurological problems, along with veterans and older Americans with chronic medical problems, requested this action.
Last week, Tilray Brands, Canopy Growth, Aurora Cannabis, SNDL, and Cronos Group reacted positively to the news of Trump considering reclassifying marijuana. This move could open up opportunities for more research on the plant’s medical benefits.
President Trump’s decision follows a review process initiated by President Joe Biden in 2022 to potentially reclassify marijuana as a Schedule 3 drug. While this action does not legalize or decriminalize marijuana, it could pave the way for further research and development in the medical field.
If Trump proceeds with the executive order, it would continue the efforts started by Biden’s administration to reclassify marijuana. The process involves moving marijuana from Schedule 1 to Schedule 3, which could make it easier for legal markets in states with marijuana laws to operate without facing federal restrictions.
The decision to reclassify marijuana has garnered support from voters across party lines, with a majority favoring the move to Schedule 3. While this change may not fully legalize marijuana, it could streamline research efforts and provide more opportunities for studying the plant’s potential benefits and drawbacks.
Overall, the reclassification of marijuana could have wide-ranging implications for the medical field, legal markets, and research institutions, potentially opening up new avenues for exploring the plant’s therapeutic properties.